LifeCell Diagnostics Becomes the First in India to Launch Comprehensive Preeclampsia
The addition of a new biomarker to the screening panel enables detection of late-onset
preeclampsia in the third trimester
Chennai, 20th July 2021:
LifeCell, one of the leading diagnostics and healthcare solutions
companies, is now the first provider in India to offer screening for both early-onset and late-
onset preeclampsia during pregnancy. This launch is a significant milestone as the currently
available diagnostic tests in the country screen only for early-onset preeclampsia. LifeCell has
previously introduced the first-trimester preeclampsia screening based on detection of
placental growth factor (PIGF) levels. However, the addition of another important biomarker,
sFLT-1 (soluble FMS-like tyrosine kinase-1) in the screening panel will enable the prediction of
preeclampsia and help in accurate diagnosis even in the third trimester.
Preeclampsia, a serious complication of pregnancy, affects 8-10% of Indian women and is
characterized by high blood pressure that can damage major organs. Additionally, it can also
lead to slow or restricted growth of the fetus, preterm birth, stillbirth, low birth weight or even
prove fatal. Late-onset preeclampsia occurs in about 75-80% of all cases of preeclampsia and is
associated with maternal morbidity (metabolic syndrome, impaired glucose tolerance, obesity,
dyslipidemia, chronic hypertension), as well as normal birth weight and placental volume.
LifeCell’s comprehensively designed preeclampsia screening tests adhere to protocols defined
by the Fetal Medicine Foundation and the National Institute for Health and Care Excellence
(NICE). Additionally, the tests provide reliable results based on the biochemical markers along
with ultrasound findings and the mother’s medical history. The early-onset preeclampsia
screening test is performed along with combined first-trimester screening (CFTS) to evaluate
the levels of PIGF in the mother’s blood. As the ASPRE trial demonstrated, the early detection
of preeclampsia using CFTS can be managed with the administration of low-dose aspirin in high-
risk women, reducing the risk of preterm preeclampsia by more than 60%.
Additionally, LifeCell's late-onset preeclampsia screening evaluates a different biomarker, sFlt-
1. In women who develop pre-eclampsia, the levels of sFlt-1 are thought to be higher than
those seen in normal pregnancy. The screening for late-onset preeclampsia, thus, measures the sFlt-1 and PlGF ratio which effectively allows identification of low-risk pregnancies that are at a
high risk of developing preeclampsia.
Dr. Chinmayee Rathe, Fetal Medicine Consultant, Resolution Fetal Medicine Centre,
Hyderabad said, “Preeclampsia is a pregnancy-specific complication leading to maternal
hypertension and multisystem disorders which can be life-threatening to the mother as well as
the fetus. Since treatment for this condition is ultimately delivering, it remains an important
cause of iatrogenic prematurity. Reducing the incidence and/or severity of preeclampsia can
improve perinatal health significantly. Women who have preeclampsia are at higher risk of
medical problems in later life and thus screening and prevention of preeclampsia in pregnancy
is a very important health intervention"
Dr. Chander Lulla Consultant Sonologist & Fetal Medicine Specialist, “India is the stillbirth
capital of the world. Preeclampsia is an important cause of death and complications for the
mother and baby. Screening for preeclampsia at 11-13 weeks can identify about 90% of women
who develop early Preeclampsia and administration of aspirin,150 mg/day reduces the rate of
early Preeclampsia by about 90%. It is strongly recommended to provide Preeclampsia
screening to our prospective mothers.“;
This new addition in the testing suite of LifeCell Diagnostics will bolster its commitment to
provide relevant and reliable test results that not only help doctors make the right clinical
decisions but also improve maternal and newborn health.
Established in 2004 , LifeCell is India’s first and largest community stem cell bank, enjoying the
trust of over 3,50,000 parents. We are the only player in the industry offering comprehensive
stem cell solutions including the novel initiative of community stem cell banking and point-of-
care stem cell therapy for orthopaedic and vascular specialities. LifeCell’s Diagnostics division
started in 2012, offers the most advanced and comprehensive diagnostic programs for
preconception, prenatal as well as newborn health in more than 1200 hospitals across 200
cities. We have spearheaded various biochemical, genetic, and cytogenetic testing services
including COVID detection and related patient management tests. Our innovative healthcare &
diagnostic solutions are aimed at addressing the challenge of high infant & maternal mortality
rates in the country and to provide actionable insights to help clinicians make better decisions,
thus, promoting health for the generations to come.